NCT04111497

Glasdegib for Chronic Graft-Versus-Host Disease

A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Fred Hutchinson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.

Detailed description

OUTLINE: This is a phase I/II study. Patients receive glasdegib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.

Conditions

• Chronic Graft Versus Host Disease
• Fasciitis

Interventions

Type	Name	Description
DRUG	Glasdegib	Given PO

Timeline

• Start date: 2019-12-03
• Primary completion: 2023-08-23
• Completion: 2023-08-23
• First posted: 2019-10-01
• Last updated: 2024-10-29
• Results posted: 2024-10-29

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study